Literature DB >> 6846707

Management of acute ischemia of the upper extremity.

J J Ricotta, P A Scudder, J A McAndrew, J A De Weese, A G May.   

Abstract

Records of 76 patients who presented with ischemia of the upper extremity from 1966 to 1981 were reviewed. Patients were divided into three groups according to cause: Group 1, emboli from the artery; Group 2, ischemia after catheter injury; and Group 3, ischemia due to lesions of the axillary and subclavian arteries. Management varied among the three groups. Long-term anticoagulation therapy was helpful in Group 1 patients in preventing reembolization. Forty percent of patients with catheter-related trauma required angioplasty of some sort in addition to embolectomy. Management of Group 3 patients was most difficult and the results least acceptable (three patients required amputation). Management of this type of ischemia must be individualized; it should vary according to the underlying disorder.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6846707     DOI: 10.1016/0002-9610(83)90117-4

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

Review 1.  Nonoperative Management of Acute Upper Limb Ischemia.

Authors:  Victor W Wong; Melanie R Major; James P Higgins
Journal:  Hand (N Y)       Date:  2016-03-08

2.  Acute upper limb ischemia due to cardiac origin thromboembolism: the usefulness of percutaneous aspiration thromboembolectomy via a transbrachial approach.

Authors:  Sung-Kwan Kim; Hyo-Sung Kwak; Gyoung-Ho Chung; Young-Min Han
Journal:  Korean J Radiol       Date:  2011-08-24       Impact factor: 3.500

3.  Local thrombolytic infusion in arterial ischemia of the upper limb: mid-term results.

Authors:  M Coulon; P Goffette; R F Dondelinger
Journal:  Cardiovasc Intervent Radiol       Date:  1994 Mar-Apr       Impact factor: 2.740

4.  Critical ischaemia of the upper limb.

Authors:  M S Quraishy; S J Cawthorn; A E Giddings
Journal:  J R Soc Med       Date:  1992-05       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.